{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red33\green33\blue33;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red119\green119\blue119;
\red80\green80\blue80;
\red37\green37\blue37;
\red247\green247\blue247;
\red151\green151\blue151;
\red21\green137\blue21;
\red246\green246\blue246;
\red51\green51\blue51;
\red56\green124\blue43;
\red254\green254\blue0;
\red0\green114\blue54;
\red106\green144\blue39;
\red181\green79\blue104;
\red112\green112\blue112;
\red255\green255\blue102;
\red214\green214\blue214;
\red187\green187\blue187;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red239\green122\blue2;
\red255\green255\blue174;
\red204\green255\blue255;
\red255\green255\blue204;
\red255\green204\blue0;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red240\green240\blue240;
\red20\green93\blue164;
\red105\green105\blue105;
\red227\green227\blue227;
\red188\green41\blue30;
\red190\green237\blue228;
\red238\green238\blue238;
\red233\green233\blue233;
\red61\green61\blue61;
\red218\green218\blue218;
\red227\green232\blue250;
\red70\green70\blue68;
\red250\green250\blue250;
\red255\green194\blue211;
\red236\green236\blue236;
\red183\green242\blue206;
\red127\green127\blue127;
\red71\green120\blue194;
\red102\green0\blue102;
\red182\green231\blue243;
\red190\green190\blue252;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red153\green153\blue153;
\red214\green9\blue9;
\red102\green102\blue102;
\red185\green185\blue185;
\red240\green248\blue255;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red172\green172\blue172;
\red9\green56\blue84;
\red118\green118\blue118;
\red153\green255\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Helvetica;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics LLC, Not Reported in Fed....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_97}{\*\bkmkend co_document_97}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart Ic22a8510929f11e5b08589a37876010a_Target}{\*\bkmkend Ic22a8510929f11e5b08589a37876010a_Target}
\par 
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
2015 WL 7430082
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, N.D. Ohio, Eastern Division.
\par 
}
}
}
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf27 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
The CLEVELAND CLINIC FOUNDATION, et. al, Plaintiffs,
\par 
}
}
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf27 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5046704989)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
TRUE HEALTH DIAGNOSTICS LLC
}}}
{\b0 \cf27 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
CASE NO. 1:15 CV 2331
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed 11/18/2015
\par 
}
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_97}{\*\bkmkend co_attorneysAndLawFirms_97}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0485701801&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Joshua A. Friedman
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0199966101&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Todd R. Tucker
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Calfee, Halter & Griswold, Cleveland, OH, for Plaintiff.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0337247201&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam L. Marchuk
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0474361801&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Caroline A. Teichner
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0422215101&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Mark T. Smith
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321413601&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael R. Osterhoff
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Perkins Coie, Chicago, IL, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0466373901&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David Sporar
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Brouse McDowell, Cleveland, OH, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0385311901&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kerri L. Keller
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Brouse McDowell, Akron, OH, for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_97}{\*\bkmkend co_opinion_97}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I789e45d2377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I789e45d2377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78a71f71377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78a71f71377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb600 
Memorandum of Opinion and Order
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0152496001&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
PATRICIA A. GAUGHAN
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, United States District Judge
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ab8c41377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ab8c41377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ab8c41377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ab8c41377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
INTRODUCTION
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_97}{\*\bkmkend co_pp_sp_999_1_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This matter is before the Court upon Plaintiff\rquote s [
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
sic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] Motion for Temporary Restraining Order and Preliminary Injunction (Doc. 7). Plaintiffs, The Cleveland Clinic Foundation (\u8220\'3fCCF\u8221\'3f) and Cleveland HeartLab (\u8220\'3fHeartLab\u8221\'3f) (CCF and Heartlab, sometimes, collectively \u8220\'3fplaintiff\u8221\'3f) filed this lawsuit against defendant, True Health Diagnostics. This is a patent infringement case. For the reasons that follow, the motion is DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ac0171377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ac0171377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ac0171377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ac0171377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
FACTS
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ac0171377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ac0171377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
1. The patents
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 2003, researchers at CCF developed a test that assesses a patient\rquote s risk for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCVD\u8221\'3f). The test, called Myeloperoxidase or \u8220\'3fMPO\u8221\'3f testing, analyzes inflammation of the blood vessels. MPO is an enzyme released by white blood cells when inflammation occurs in the body. (Penn Decl. at \u182\'3f 18). When an artery wall is damaged or becomes inflamed, MPO is released into the blood stream in an effort to kill bacteria. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Thus, MPO is an early symptom of many types of CVD. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 9).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
CCF filed a series of patent applications relating to MPO. The Patent and Trademark Office (\u8220\'3fPTO\u8221\'3f) granted CCF\rquote s applications, and it is currently the owner of the three patents at issue in this lawsuit: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,223,552 (\u8220\'3fthe \lquote 552 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,459,286 (\u8220\'3fthe \lquote 286 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 8,349,581 (\u8220\'3fthe \lquote 581 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which issued on May 29, 2007, has since been the subject of validity challenges by competitors in two reexamination proceedings before the PTO. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was confirmed valid in both proceedings, most recently in 2011.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patents teach a method of analyzing MPO biomarkers in a patient\rquote s blood sample to predict a patient\rquote s potential for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibe73170c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
heart disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. They do so by comparing the level of MPO found in the patient\rquote s blood sample with levels of MPO in control subjects to see if the patient has elevated levels of MPO.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ad8811377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ad8811377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ad8811377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ad8811377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
2. Plaintiff\rquote s development and commercialization of MPO testing
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 2009, CCF launched HeartLab to begin commercialization of MPO testing. HeartLab is the exclusive licensee of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 10). CCF and HeartLab have invested millions of dollars in their effort to build the MPO testing market. (Orville Decl. \u182\'3f 12). They are conducting ongoing medical and scientific studies, sought FDA approvals, and obtained Medicare reimbursement status for MPO testing. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at \u182\'3f 8). They have focused considerable effort on developing stringent manufacturing and quality standards and also invested in educational programs about MPO testing. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; Penn Decl. \u182\'3f\u182\'3f26, 29-38).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
HeartLab both performs lab analysis of patients\rquote  blood samples at HeartLab and, when volume is large enough, it will manufacture MPO testing kits for sale to other labs. (Orville Decl. \u182\'3f 11). CCF\rquote s and HeartLab\rquote s efforts to develop and commercialize MPO testing have been quite successful. At its inception, HeartLab had eight employees who performed only a few hundred MPO tests. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Orville Decl. \u182\'3f\u182\'3f 9, 13). It now has 140 employees who will perform hundreds of thousands of MPO tests in 2015. (Orville Decl. \u182\'3f\u182\'3f 9-10, 13).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ae9981377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ae9981377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78ae9981377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78ae9981377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
3. The alleged infringing actions
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_97}{\*\bkmkend co_pp_sp_999_2_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Defendant, a lab services company that performs CVD testing, was formed in March 2014. In September of 2015, defendant purchased some of the assets of Health Diagnostics Lab (\u8220\'3fHDL\u8221\'3f) in a bankruptcy proceeding. Prior to its bankruptcy, HDL had used HeartLab for its MPO testing through a Laboratory Services Agreement. In its bid for HDL\rquote s assets, defendant sought HDL\rquote s customer list, including HDL\rquote s MPO testing customers, but expressly excluded HDL\rquote s Laboratory Services Agreement with HeartLab.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Concerned that defendant might use the technology in the MPO patents without authorization, HeartLab\rquote s CEO emailed defendant on September 14, 2015, to advise defendant that use of the MPO testing procedures would infringe the patents at issue. Defendant did not respond to the email. After learning anecdotally that one of defendant\rquote s salespersons was representing to former HDL customers that defendant was offering an MPO test from HeartLab and was HeartLab\rquote s exclusive partner, plaintiff began an investigation to determine if defendant was offering MPO testing.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In mid-October, HeartLab acquired one of defendant\rquote s lab tests which showed that defendant was conducting MPO tests. Shortly thereafter, HeartLab discovered more of defendant\rquote s lab reports with MPO testing results. The reports all use different ranges for establishing the risk of a CVD event, which HeartLab claims \u8220\'3findicates a lack of quality ...[and that defendant] is not adhering to standard laboratory regulations and procedures.\u8221\'3f (Pl.\u8217\'3fs Br. at 15). According to HeartLab, defendant\rquote s lack of quality control standards is \u8220\'3fputting the entire MPO market segment at risk.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Plaintiff also states that \u8220\'3fbecause most of the MPO market views ... HeartLab as the sole source of MPO as well as the MPO innovator, any misstep by [defendant] will in all likelihood be blamed on ... HeartLab\u8211\'3fespecially in view of [defendant\rquote s] insinuation that it is a partner of ... HeartLab.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 18).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thereafter, plaintiff filed this lawsuit alleging that defendant infringes the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It now moves for a temporary restraining order and preliminary injunction enjoining defendant from infringing the patents-in-suit. Defendant opposes plaintiff\rquote s motion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b0e371377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b0e371377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b0e371377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b0e371377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
ANALYSIS
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR65&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 65
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 governs the issuance of temporary restraining orders and preliminary injunctions.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In order to obtain a preliminary injunction, a patentee must show: \u8220\'3f(1) reasonable likelihood of success on the merits; (2) irreparable harm; (3) that the balance of hardships tips in its favor; and (4) the impact of the injunction on the public interest.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002555365&pubNum=0000506&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_506_1356&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1356" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Jack Guttman, Inc. v.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Kopykake Enters
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
., 302 F.3d 1352, 1356 (Fed.Cir.2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fThe denial of a preliminary injunction pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS283&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 283
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is within a district court\rquote s discretion.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2016650083&pubNum=0006538&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_6538_335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_335" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Novo Nordisk v. Sanofi-Aventis U.S. LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 290 Fed. Appx. 334, 335 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit will \u8220\'3freverse such a decision only when an appellant demonstrates that the factors relied on by the district court [were] clearly erroneous and that a denial of the preliminary relief sought would amount to an abuse of the court\rquote s discretion upon reversal of an erroneous finding. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1992135169&pubNum=0000350&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_350_882&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_882" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
New Eng. Braiding Co. v. A.W. Chesterton Co.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 970 F.2d 878, 882 (Fed.Cir.1992)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(internal quotations omitted)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b29121377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b29121377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b29121377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b29121377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
DISCUSSION
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b29121377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b29121377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
1. Likelihood of success on the merits
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff argues that it demonstrates a likelihood of success on the merits as to both infringement and validity. According to plaintiff, the claim construction process is straightforward and requires the construction of only two claim terms. Plaintiff also argues that its patents are valid and have successfully gone through an extensive reexamination process. Defendant argues that plaintiff\rquote s patents are invalid because they are based on ineligible subject-matter. Defendant also disputes that plaintiff establishes a likelihood of success on the issue of infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_97}{\*\bkmkend co_pp_sp_999_3_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Because the Court finds that plaintiff fails to show a likelihood of success on the merits as to validity, the Court will address this issue first.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The presumption of validity of a patent is a procedural device that places the burden of going forward and the ultimate burden of persuasion at trial on one attacking the validity of a patent. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS282&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 282 (1988)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985113938&pubNum=0000350&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_350_1270&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1270" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roper Corp. v. Litton Systems, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 757 F.2d 1266, 1270 (Fed.Cir.1985)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
. However, at the preliminary injunction stage, because of the extraordinary nature of the relief, the patentee carries the burden of showing likelihood of success on the merits with respect to the patent\rquote s validity, enforceability, and infringement.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991066244&pubNum=0000350&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_350_870&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_870" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nutrition 21 v. United States
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 930 F.2d 867, 870 (Fed. Cir. 1991)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, the burden is on the plaintiff to make a \u8220\'3fclear showing\u8221\'3f that the patent is valid. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Upon review, the Court finds that plaintiff fails to make a clear showing that the patents-in-suit are valid. Pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, [w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is limited, however, and does not cover \u8220\'3flaws of nature, natural phenomena, and abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd v. CLS Bank International
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. 2347, 2354 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In \u8220\'3fapplying the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 exception, we must distinguish between patents that claim the \u8216\'3fbuilding block[s]\u8217\'3f of human ingenuity and those that integrate the building blocks into something more.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_708_1303&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1303" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. 1289, 1303 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court employed a two-part test \u8220\'3ffor distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Courts must tread carefully because \u8220\'3fat some level, all inventions... embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. First, the court must determine \u8220\'3fwhether the claims at issue are directed at a patent-ineligible concept.\u8221\'3f If the claims are so directed, the Court must proceed to step two, which involves a determination as to whether the patent contains an \u8220\'3finventive concept,\u8221\'3f which is described as \u8220\'3fan element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (Internal citations and quotations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court addressed the validity of a patent designed to \u8220\'3fhelp doctors who use thiopurine drugs to treat patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39e7bac475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
autoimmune diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 determine whether a given dosage level is too low or too high.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Specifically, the patent described a process of evaluating the safety of the concentrations of a particular metabolite in a person\rquote s blood. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Federal Circuit determined that in addition to the natural correlations, the patent claimed specific steps of administering a thiopourine drug and determining the resulting metabolite level. As such, the Federal Circuit determined that the patent was directed at patent-eligible subject matter. The Supreme Court reversed, finding:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_97}{\*\bkmkend co_pp_sp_999_4_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 To put the matter more succinctly, the claims inform a relevant audience about certain laws of nature; any additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community; and those steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1298.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In a series of cases following 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit invalidated a number of patents directed at medical testing. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. V. Sequenon, Inc.,
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 788 F.3d 1371 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1- & BRCA2-
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Based Hereditary Cancer Test Patent Litigation
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d 775 (Fed. Cir. 2014) (affirming denial of preliminary injunction based on patent-ineligible subject matter with respect to patents directed at methods to identify mutations in DNA sequences); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029241057&pubNum=0006538&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PerkinElmer, Inc. v. Intema Ltd.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 496 Fed. Appx. 65 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(patent disclosing specific screening methods to estimate the risk of fetal 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibc288ad2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Down syndrome
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 held invalid).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, by plaintiff\rquote s own admission, its \u8220\'3fMPO Patents analyze the myeloperoxidase biomarker.\u8221\'3f Although plaintiff argues that its patents contain an inventive concept because \u8220\'3fmeasuring the MPO levels to determine the risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not known in the prior art,\u8221\'3f the Court is not convinced at this stage in the litigation that this constitutes an inventive concept. Rather, it appears that the correlation between MPO levels and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is more akin to a law of nature. And, as defendant correctly notes, although the \u8220\'3fdiscovery\u8221\'3f of a law of nature may be significant, the significance alone does not render the discovery patentable.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court is further not convinced that plaintiff has demonstrated that the patents-in-suit contain \u8220\'3fan element or combination of elements\u8221\'3f sufficient to satisfy step two of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test. Plaintiff simply argues that its patents require \u8220\'3fmeasurement of a closed set of specific bodily samples\u8221\'3f and, therefore, its patents apply a \u8220\'3fphenomenon in a combination of steps that has never been done before.\u8221\'3f At this point in the litigation, the Court disagrees. Measuring a sample of blood or blood product
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012037655832_ID0EOUAE_97}{\*\bkmkend co_fnRef_B00012037655832_ID0EOUAE_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012037655832_97" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 appears to be a \u8220\'3fwell-understood, routine and conventional activity\u8221\'3f known in the scientific community.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the first time in its reply brief, plaintiff appears to argue that the patents satisfy 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they require the \u8220\'3funity of two crucial innovations.\u8221\'3f Namely, plaintiff claims that the patents measure MPO using certain \u8220\'3fclaimed\u8221\'3f techniques and recognize that MPO can predict CVD risk. Plaintiff, however, wholly fails to point the Court to specific language contained in the patents that supports these propositions. Rather, plaintiff merely states that the claims are \u8220\'3fdrawn to a novel application and implementation of MPO testing,\u8221\'3f but fails to offer any explanation beyond this general statement. Plaintiff makes no other argument, nor does plaintiff point to any specific claim language in any of the patents-in-suit that supports a finding of validity.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022037655832_ID0ERWAE_97}{\*\bkmkend co_fnRef_B00022037655832_ID0ERWAE_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022037655832_97" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As such, the Court finds that plaintiff fails to make a \u8220\'3fclear showing\u8221\'3f that its patent is valid in light of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_97}{\*\bkmkend co_pp_sp_999_5_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Having concluded that plaintiff fails to establish a likelihood of success on the merits with respect to validity, the Court need not address infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b947e1377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b947e1377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78b947e1377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78b947e1377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
2. Irreparable harm
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032037655832_ID0ERYAE_97}{\*\bkmkend co_fnRef_B00032037655832_ID0ERYAE_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032037655832_97" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court further finds that plaintiff fails to demonstrate that it will suffer irreparable harm absent the issuance of a temporary restraining order or preliminary injunction. Plaintiff argues that it will suffer loss of goodwill and damages to its reputation. Plaintiff claims that a \u8220\'3fsingle false result in one of defendant\rquote s dubious tests could tar the entire MPO market segment.\u8221\'3f Plaintiff also argues that defendant\rquote s tests are \u8220\'3fsubstandard and inconsistent.\u8221\'3f The Court agrees with defendant, however, that plaintiff fails to produce any evidence supporting these assertions. Although plaintiff produces an affidavit supporting the proposition that defendant\rquote s tests are unreliable and will cause confusion, there is no evidence that any confusion or errors actually occurred. Plaintiff\rquote s evidence is speculative at best. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021504350&pubNum=0004637&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bettcher Industries, Inc. v. Bunzl USA, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 692 F.Supp.2d 805 (N.D. Ohio 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004243677&pubNum=0004637&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lopes v. International Rubber Distributors, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 309 F.Supp.2d 972 (N.D. Ohio 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Moreover, in response to plaintiff\rquote s speculative evidence, defendant produced evidence indicating that it has 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 received any customer complaints regarding false positive or negative results or confusion about the values used in defendant\rquote s testing. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Ward Decl. At \u182\'3f\u182\'3f 16-17; Grottenthaler Decl. At \u182\'3f 18-19.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For these same reasons, the Court rejects plaintiff\rquote s argument that monetary harm is incalculable in this case because of the nature of the market. Plaintiff claims that the market for MPO testing is new and growing and that \u8220\'3fit may not be able to keep financing its efforts to grow the market.\u8221\'3f Again, however, plaintiff offers no evidence in support of this assertion. To the contrary, plaintiff\rquote s own allegations and evidence show that plaintiff has significantly grown its company from an original eight employees to a current 140. Plaintiff also points out that it now sells \u8220\'3fhundreds of thousands\u8221\'3f of MPO tests. As such, the Court rejects defendant\rquote s argument that monetary harm is incalculable.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff also argues that defendant usurped market share when it purchased the customer list from HDL. Plaintiff, however, fails to point to any evidence that it lost a single customer as a result of defendant\rquote s alleged infringement. Thus, plaintiff\rquote s reliance on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033138987&pubNum=0000506&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Trebro Mfg. v. FireFly Equip
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
., LLC, 748 F.3d 1159 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is misplaced.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042037655832_ID0EF5AE_97}{\*\bkmkend co_fnRef_B00042037655832_ID0EF5AE_97}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042037655832_97" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In all, the Court finds that plaintiff fails to establish irreparable harm.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78bc2e11377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78bc2e11377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78bc2e11377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78bc2e11377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
3. Balance of hardships/public interest
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_97}{\*\bkmkend co_pp_sp_999_6_97}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff argues that once a Court finds likelihood of success on the merits and irreparable harm, an injunction should be issued unless the balance of hardships weighs \u8220\'3fdecidedly\u8221\'3f in favor of defendant. Here, however, the Court found neither likelihood of success on the merits nor irreparable harm. Thus, the Court finds that this factor does not weigh in favor of the issuance of a restraining order or injunction. For the same reasons, the public interest is not served by the issuance of a restraining order or injunction.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78bca341377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78bca341377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I78bca341377211ebb3e1c97d343d9}{\*\bkmkend co_anchor_I78bca341377211ebb3e1c97d343d9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
CONCLUSION
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, Plaintiff\rquote s [
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
sic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] Motion for Temporary Restraining Order and Preliminary Injunction is DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IT IS SO ORDERED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_97}{\*\bkmkend co_allCitations_97}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2015 WL 7430082
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012037655832_97}{\*\bkmkend co_footnote_B00012037655832_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012037655832_ID0EOUAE_97" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Plaintiff does not point to any specific language in its patents in making this argument. The Court notes, however, that the bodily samples identified in the patents consist of \u8220\'3fblood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
leukocytes
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 selected from the group consisting of neutrophils and monocytes, or any combination thereof.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022037655832_97}{\*\bkmkend co_footnote_B00022037655832_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022037655832_ID0ERWAE_97" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Although plaintiff repeatedly notes that the patents-in-suit were subject to extensive reexamination processes, those processes predated the Supreme Court\rquote s decision in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032037655832_97}{\*\bkmkend co_footnote_B00032037655832_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032037655832_ID0ERYAE_97" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
According to plaintiff, irreparable harm is presumed if plaintiff clearly establishes validity and infringement. The case plaintiff relies on, however, was abrogated and is no longer good law. See, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026328193&pubNum=0000506&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Robert Bosch, LLC v. Pylong Mfg. Co.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 659 F.3d 1142 (Fed. Cir. 2011)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
(abrogating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1983146007&pubNum=0000350&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_350_1581&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1581" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Smith Int\rquote l, Inc. v.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Hughes Tool Corp.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 718 F.2d 1573, 1581 (1983)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 in light of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009155959&pubNum=0000780&originatingDoc=Ic22a8510929f11e5b08589a37876010a&refType=RP&fi=co_pp_sp_780_391&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_391" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
eBay Inc. v. MercExchange, L.L.C.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 547 U.S. 388, 391 (2006)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042037655832_97}{\*\bkmkend co_footnote_B00042037655832_97}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042037655832_ID0EF5AE_97" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Trebo
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 involved a unique market in which product sales were extremely limited. The Federal Circuit held that the district court erred in rejecting evidence showing \u8220\'3flikely loss of market share and loss of access to customers.\u8221\'3f Here, by plaintiff\rquote s own admission, the market for MPO testing is much larger than the market for sod harvesters, the product at issue in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Trebo
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. Moreover, plaintiff offers no evidence of lost market share or loss of access to customers.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf25 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf25 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf25 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf25 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf25 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf25 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }